TX-SOFTSERVE
12.7.2022 13:07:09 CEST | Business Wire | Press release
SoftServe , a leading digital authority and consulting company, has been named a Major Contender by Everest Group's Healthcare Payer Digital Services PEAK Matrix® Assessment 2022. The recognition marks the first year that SoftServe has participated in Everest Group's annual healthcare payer digital services marketplace assessment.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220712005092/en/
"Being named as a Major Contender in Everest Group's PEAK Matrix for Healthcare Payer Digital Services acknowledges SoftServe's significant digital healthcare experience," said Adam Gabrault, President, Strategic Verticals & Industry Solutions, North America at SoftServe. "It demonstrates how we accelerate outcomes across the healthcare continuum by providing our clients with innovative solutions and deep domain expertise."
Everest Group's Healthcare Payer Digital Services PEAK Matrix Assessment analyzes the relative market impact and overall capabilities of 26 service and technology providers. The report focuses on market size and growth, digital service themes for healthcare payers, and assessments of capabilities and market success-related dimensions. In addition, Everest Group offers independent remarks on these service providers.
SoftServe was recognized as a Major Contender by demonstrating its next-generation healthcare services delivery capabilities with the company's Human360® Member Digital Experience Platform. The member-centric solution enhances data aggregation, engagement, and care management. Everest Group highlighted SoftServe's ability to leverage its strategic partner ecosystem to augment and manage data. The report also notes SoftServe's positive client feedback on price flexibility, technical expertise, and client management.
"Business themes such as payer-provider collaboration, interoperability, value-based care, and member experience are driving the demand for digital adoption among payers,” said Chunky Satija, Vice President at Everest Group. “Along with its strategic focus of enhancing its digital capabilities through COEs and a strong partner ecosystem, SoftServe is also augmenting its vertical capabilities by building healthcare native IPs, such as DataMask solution and Member Digital Experience platform, to drive value for clients. SoftServe’s strong technical expertise and delivery excellence coupled with its focus on providing innovative price constructs has enabled it to be positioned as a Major Contender in Healthcare Payer Digital Services PEAK Matrix® Assessment 2022."
View an extract of the Healthcare Payer Digital Services PEAK Matrix Assessment 2022 here .
About SoftServe
SoftServe is a digital authority that advises and provides at the cutting-edge of technology. We reveal, transform, accelerate, and optimize how enterprises and software companies do business. Our end-to-end solutions and expertise deliver innovation, quality, and speed across the healthcare, retail, energy, manufacturing, and financial services verticals. We empower enterprises and software companies to (re)identify differentiation, accelerate solution development, and vigorously compete in today’s marketplace—no matter where you are in your journey.
Visit our website , blog , LinkedIn , Facebook , and Twitter .
For additional background on the work SoftServe has done to be named a Major Contender in the healthcare payer digital services marketplace, please come to our Healthcare & Life Sciences page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220712005092/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
SES Publishes FY2025 EU Taxonomy Restatement31.7.2026 07:30:00 CEST | Press release
SES today published a restatement of its FY2025 EU Taxonomy (Article 8) disclosure. The restatement updates the FY2025 EU Taxonomy disclosure included in the 2025 Annual Report and supersedes the previously published disclosure. The FY2025 EU Taxonomy Restatement is available on the SES website: https://www.ses.com/sites/ses_v2/files/investor-files/2026-07/EU_Taxonomy_Report_Restatement_2025.pdf Follow us on: X | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where they are. With integrated multi-orbit satellites and our global terrestrial network, we deliver resilient, seamless connectivity and the highest quality video content to those shaping what’s next. Following our Intelsat acquisition, we now offer more than 100 years of combined global industry l
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom